NCT01452750已完成3 期
A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Non-steroidal Anti-inflammatory Drug (NSAID).
Takeda0 个研究点目标入组 642 人开始时间: 2011年10月最近更新:
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 642
- 主要终点
- Recurrence rate of gastric or duodenal ulcer within 24 weeks
研究概览
简要总结
The purpose of this study is to evaluate the efficacy of TAK-438, once daily (QD), compared to AG-1749 (Lansoprazole) in patients with a history of gastric or duodenal ulcer who require long-term therapy of non-steroidal anti-Inflammatory drug (NSAID).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants who require continuous NSAID therapy during the treatment period with the study drug
- •Participants who have a history of ulcer in stomach or duodenum, endoscopically confirmed
- •Outpatient (including inpatient for examinations)
排除标准
- •Participants scheduled to change the type and dosage regimen of NSAID
- •Participants with ulcers or bleeding in stomach or duodenum, endoscopically confirmed
- •Participants with small intestine bleeding, large intestine bleeding, or gastrointestinal bleeding of unknown etiology
- •Participants who have a history of surgery which affects gastric acid secretion (e.g., resection of upper gastrointestinal tract, vagotomy) or who are scheduled to undergo such surgery
- •Participants with a previous or current history of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorders
- •Participants with a previous or current history of aspirin-induced asthma
研究组 & 干预措施
TAK-438 10 mg QD
Experimental
干预措施: TAK-438 (Drug)
TAK-438 10 mg QD
Experimental
干预措施: Placebo (Drug)
TAK-438 20 mg QD
Experimental
干预措施: TAK-438 (Drug)
TAK-438 20 mg QD
Experimental
干预措施: Placebo (Drug)
Lansoprazole 15 mg QD
Active Comparator
干预措施: Lansoprazole (Drug)
Lansoprazole 15 mg QD
Active Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Recurrence rate of gastric or duodenal ulcer within 24 weeks
时间窗: 24 weeks
Mucosal defects with a white coating of 3 mm or larger will be determined as ulcers. Recurrence rate of gastric or duodenal ulcer within 24 weeks will be calculated for each treatment group.
次要结局
- Recurrence rate of gastric or duodenal ulcer within 12 weeks(12 weeks)
- Gastric mucosal injury(24 Weeks)
- Duodenal mucosal injury(24 weeks)
- Occurrence rate of hemorrhagic lesion in stomach or duodenum(24 weeks)
- Time to recurrence of gastric or duodenal ulcer(24 weeks)
研究者
相似试验
已完成
3 期
Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose AspirinGastric UlcersDuodenal UlcersNCT01452763Takeda621
已完成
3 期
Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gastric UlcerGastric UlcerNCT01452711Takeda482
已完成
3 期
Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive EsophagitisErosive EsophagitisNCT01452698Takeda409
已完成
3 期
Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Duodenal UlcerDuodenal UlcerNCT01452724Takeda372
已完成
3 期
Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroesophageal Reflux DiseaseNon-erosive Gastroesophageal Reflux DiseaseNCT01474369Takeda827